(Q47322356)

14 January 2018

title

Expression of receptor activator of NF-kappaB ligand (RANKL) mRNA in human multiple myeloma cells (English)

1 reference

14 January 2018

0 references

Ulrike Heider

1

1 reference

14 January 2018

Ivana Zavrski

2

1 reference

14 January 2018

Christian Jakob

3

1 reference

14 January 2018

Katharina Bängeroth

4

1 reference

14 January 2018

Claudia Fleissner

5

1 reference

14 January 2018

Corinna Langelotz

6

1 reference

14 January 2018

Kurt Possinger

7

1 reference

14 January 2018

Lorenz C Hofbauer

8

1 reference

14 January 2018

Volker Viereck

9

1 reference

14 January 2018

Orhan Sezer

10

1 reference

14 January 2018

publication date

15 June 2004

1 reference

14 January 2018

Journal of Cancer Research and Clinical Oncology

published in

1 reference

14 January 2018

volume

130

1 reference

14 January 2018

issue

8

1 reference

14 January 2018

page(s)

469-474

1 reference

14 January 2018

https://scigraph.springernature.com/pub.10.1007/s00432-004-0578-3

exact match

0 references

cites work

Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma.

1 reference

12 December 2020

Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion

1 reference

12 December 2020

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma

1 reference

12 December 2020

A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases

1 reference

12 December 2020

Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines

1 reference

12 December 2020

High levels of interleukin-6 are associated with low tumor burden and low growth fraction in multiple myeloma

1 reference

12 December 2020

Osteoclast differentiation factor in human osteosarcoma cell line

1 reference

12 December 2020

Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells

1 reference

12 December 2020

Immunohistochemical study of intermediate filament proteins on routinely processed, celloidin-embedded human temporal bone sections by using a new technique for antigen retrieval

1 reference

12 December 2020

Expression of breast cancer resistance protein in blast cells from patients with acute leukemia.

1 reference

12 December 2020

Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts.

1 reference

12 December 2020

Comparison of interleukin-1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma

1 reference

12 December 2020

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

1 reference

12 December 2020

Minireview: the OPG/RANKL/RANK system

1 reference

12 December 2020

The effect of a single dose of osteoprotegerin in postmenopausal women

1 reference

12 December 2020

RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma

1 reference

12 December 2020

Biology of osteoclast activation in cancer

1 reference

12 December 2020

1 reference

12 December 2020

Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity

1 reference

12 December 2020

Expression of interleukin-1beta and tumour necrosis factor-alpha in plasma cells from patients with multiple myeloma

1 reference

12 December 2020

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

1 reference

12 December 2020

Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo

1 reference

12 December 2020

Determination of three isoforms of the receptor activator of nuclear factor-kappaB ligand and their differential expression in bone and thymus

1 reference

12 December 2020

Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II-III

1 reference

12 December 2020

Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment

1 reference

12 December 2020

Liposomal daunorubicin (DaunoXome) in multiple myeloma: a modified VAD regimen using short-term infusion

1 reference

12 December 2020

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand

1 reference

12 December 2020

Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma

1 reference

12 December 2020

New insights into the pathophysiology and management of bone disease in multiple myeloma

1 reference

12 December 2020

Human bone marrow myeloma cells express RANKL

1 reference

12 December 2020

Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells

1 reference

12 December 2020

Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis

1 reference

12 December 2020

RANK ligand and osteoprotegerin in myeloma bone disease.

1 reference

12 December 2020

Coordinated cytokine expression by stromal and hematopoietic cells during human osteoclast formation.

1 reference

12 December 2020

Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression

1 reference

12 December 2020

Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families

1 reference

12 December 2020

Immunocytochemistry reveals RANKL expression of myeloma cells

1 reference

12 December 2020

Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases

1 reference

12 December 2020

10.1007/S00432-004-0578-3

Identifiers

DOI

1 reference

14 January 2018

PubMed ID

15205949

1 reference

14 January 2018